Drug Trial News

RSS

Evaluating hydronidone for the treatment of chronic hepatitis B-associated liver fibrosis

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs specifically designed to treat liver fibrosis.

18 Apr 2025

Stem cell therapy shows promise for treating advanced Parkinson's disease

A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's disease, according to results from a phase 1 clinical trial reported in Nature.

16 Apr 2025

SURMOUNT-1 trial finds tirzepatide supports long term weight control

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% or less of their so-called nadir (or lowest weight) three years after beginning treatment with tirzepatide.

11 Apr 2025

Sylvester Cancer Center launches clinical trial for patients with high-grade neuroendocrine tumors

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

9 Apr 2025

Scientists stop long-COVID symptoms in mice using a new antiviral compound

Australian scientists developed a novel antiviral that targets the SARS-CoV-2 PLpro enzyme, showing strong preclinical efficacy in reducing both acute and long COVID symptoms in mice.

9 Apr 2025

Tolebrutinib shows promise for treating non-relapsing secondary progressive multiple sclerosis

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

8 Apr 2025

Paxlovid found ineffective for long COVID relief in new trial

Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving long COVID symptoms, according to a new study published in The Lancet Infectious Diseases on April 3.

7 Apr 2025

Novel NK cell therapy shows strong response in lymphoma patients

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

4 Apr 2025

Clinical trial demonstrates safety of targeted treatment approach for deadly brain tumor in children

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators.

3 Apr 2025

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in JACC.

31 Mar 2025

Research shows clopidogrel as better long-term therapy than aspirin after PCI

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, experienced significantly better outcomes with clopidogrel rather than aspirin as their long-term antiplatelet therapy, according to research presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

31 Mar 2025

WARRIOR trial finds no impact of intensive therapy on heart events in women

An intensive three-drug regimen of heart medications did not significantly impact the rate of serious cardiovascular events at five years in women who experienced signs and symptoms of ischemia, or insufficient blood flow to the heart muscle, but had no blockages in their heart's arteries, according to research presented at the American College of Cardiology's Annual Scientific Session.

29 Mar 2025

Bentracimab reverses ticagrelor's antiplatelet effects during surgery and bleeding events

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major bleeding, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

29 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period.

29 Mar 2025

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

26 Mar 2025

New trial aims to make rectal cancer more responsive to radiation

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, has opened a phase 1 trial seeking to one day transform rectal cancer from a mostly radiation-resistant disease to one that can be cured using radiation and chemotherapy.

25 Mar 2025

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

Hepatitis B is a liver infection cause by the hepatitis B virus (HBV), and long-term hepatitis B infections that last longer than six months are considered "chronic".

24 Mar 2025

1
2
3
4
...
1148
Next

Drug Trial News

Evaluating hydronidone for the treatment of chronic hepatitis B-associated liver fibrosis

Stem cell therapy shows promise for treating advanced Parkinson's disease

SURMOUNT-1 trial finds tirzepatide supports long term weight control

Sylvester Cancer Center launches clinical trial for patients with high-grade neuroendocrine tumors

Scientists stop long-COVID symptoms in mice using a new antiviral compound

Tolebrutinib shows promise for treating non-relapsing secondary progressive multiple sclerosis

Paxlovid found ineffective for long COVID relief in new trial

Novel NK cell therapy shows strong response in lymphoma patients

Clinical trial demonstrates safety of targeted treatment approach for deadly brain tumor in children

Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEF

Research shows clopidogrel as better long-term therapy than aspirin after PCI

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

WARRIOR trial finds no impact of intensive therapy on heart events in women

Bentracimab reverses ticagrelor's antiplatelet effects during surgery and bleeding events

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

New trial aims to make rectal cancer more responsive to radiation

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News